U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 420 results

Status:
US Approved Rx (2025)
First approved in 2025

Class (Stereo):
CHEMICAL (ABSOLUTE)



PD-0325901 is an orally bioavailable inhibitor of mitogen-activated protein kinase kinases (MAPK/ERK kinases or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhib...
Status:
US Approved Rx (2023)
First approved in 2023

Class (Stereo):
CHEMICAL (ABSOLUTE)



Nirogacestat (PF-3084014) is a tetralin imidazole gamma-secretase inhibitor. Gamma-secretase, a proteolytic enzyme complex, mediates processing of several integral membrane proteins including amyloid precursor protein and Notch. This compound can inh...
Status:
US Approved Rx (2022)
First approved in 2022

Class (Stereo):
CHEMICAL (ACHIRAL)



PF-04965842 is an orally administered selective Janus kinase 1 (JAK1) inhibitor. PF-04965842 is currently in clinical trials for the treatment of autoimmune diseases.
Status:
US Approved Rx (2021)
First approved in 2021

Class (Stereo):
CHEMICAL (ABSOLUTE)



Maralixibat (Livmarli™) is a potent, apical, sodium‐dependent, bile acid transporter competitive inhibitor with minimal systemic absorption being developed by Mirum Pharmaceuticals for the treatment of rare cholestatic liver diseases including Alagil...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ABSOLUTE)



Lorlatinib is an investigational medicine that inhibits the anaplastic lymphoma kinase (ALK) and ROS1 proto-oncogene. Lorlatinib was specifically designed to inhibit tumor mutations that drive resistance to other ALK inhibitors. Lorlatinib has in vit...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ABSOLUTE)



PF-04449913 is a potent and selective inhibitor of the Hh signaling pathway through binding to the target, smoothened. PF-04449913 inhibits Hh signaling in vitro and has demonstrated significant antitumor activity in vivo. In the clinic, PF-04449913 ...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ACHIRAL)



Dacomitinib is an oral, once-daily, pan-HER inhibitor. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomtinib is being evaluated in phase 3 clinical trials against nonsmall-cell lung cancer. Direct comparison wi...
Status:
US Approved Rx (2017)
First approved in 2017

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ertugliflozin (PF-04971729) is a potent and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system. SGLT2 has become an important therapeutic target and sever...
Status:
US Approved Rx (2012)
First approved in 2012

Class (Stereo):
CHEMICAL (ACHIRAL)



Axitinib (trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with re...
Status:
US Approved Rx (2023)
First approved in 2011

Class (Stereo):
CHEMICAL (ABSOLUTE)



Crizotinib (trade name Xalkori, Pfizer, Inc.) is an anti cancer drug approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved t...